![Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ce3408bf179386422f2413d766a8d48fb3b1da69/3-Table3-1.png)
Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar
![Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ce3408bf179386422f2413d766a8d48fb3b1da69/2-Table1-1.png)
Clinical Implications of Concurrent HBsAg/HBsAb Positivity in Patients with Chronic Hepatitis B Infection | Semantic Scholar
![Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis | Scientific Reports Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-59406-4/MediaObjects/41598_2020_59406_Fig1_HTML.png)
Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis | Scientific Reports
![HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy - Shui - 2023 - Journal of Medical Virology - Wiley Online Library HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy - Shui - 2023 - Journal of Medical Virology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/137167c4-5a85-49a0-957c-2663a978f96c/jmv28549-fig-0001-m.jpg)
HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy - Shui - 2023 - Journal of Medical Virology - Wiley Online Library
![Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B | Scientific Reports Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-56015-8/MediaObjects/41598_2019_56015_Fig1_HTML.png)
Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B | Scientific Reports
![Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT - ScienceDirect Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S258900422300367X-gr1.jpg)
Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT - ScienceDirect
![Frontiers | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis Frontiers | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis](https://www.frontiersin.org/files/Articles/909660/fmed-09-909660-HTML-r1/image_m/fmed-09-909660-g001.jpg)